Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of EBITDA Margin data on record, last reported at 29.5% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 31278.0% year-over-year to 29.5%; the TTM value through Dec 2025 reached 170.35%, up 16647.0%, while the annual FY2025 figure was 163.03%, 14635.0% up from the prior year.
  • EBITDA Margin reached 29.5% in Q3 2025 per TNGX's latest filing, up from 1287.87% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 29.5% in Q3 2025 and bottomed at 1287.87% in Q2 2025.
  • Average EBITDA Margin over 5 years is 426.72%, with a median of 427.15% recorded in 2022.
  • The widest YoY moves for EBITDA Margin: up 31278bps in 2025, down -113918bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 398.9% in 2021, then dropped by -9bps to 435.33% in 2022, then fell by -26bps to 550.47% in 2023, then tumbled by -81bps to 993.68% in 2024, then soared by 103bps to 29.5% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 29.5% in Q3 2025, 1287.87% in Q2 2025, and 788.76% in Q1 2025.